Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BTC targets CME gap at $104,000 as shutdown end buoys risk

BTC targets CME gap at $104,000 as shutdown end buoys risk

CryptoSlateCryptoSlate2025/11/10 04:30
By:Andjela Radmilac

Bitcoin traders are monitoring the latest CME futures gap between Friday’s close at $104,160 and Sunday’s open at $110,370.

This six-thousand-dollar “missing” price action often attracts short-term moves. With Bitcoin near $105,900, focus is on whether the market will fill the gap or climb away from it.

When CME Bitcoin futures close on Friday, trading pauses until Sunday evening.

If Bitcoin moves sharply during this break, a chart gap appears between the last trade and the new open. Traders watch these gaps, viewing them as key indicators of price action. Over two-thirds of CME gaps since 2022 have closed within 48 hours.

The latest gap appeared as spot prices rallied over the weekend, spurred by improving sentiment in risk assets. Washington’s progress on ending the government shutdown reduced fiscal uncertainty, helping equities, crypto, and gold rebound.

The dollar weakened in early European trade, while Treasury yields eased, conditions that boost risk exposure.

BTC targets CME gap at $104,000 as shutdown end buoys risk image 0 Graph showing the price of Bitcoin futures on CME and the CME gap (yellow) from Nov. 7 to Nov. 10, 2025 (Source: TradingView)

On charts, the CME gap band runs from $104,160 to $110,370, placing the current spot roughly halfway inside it. A quick move through the lower edge could finish the “fill,” a term traders use when spot retraces into the gap’s empty zone and trades back across it.

Alternatively, if buyers defend current levels and momentum persists above $106,000, the space could remain open for a while.

Intraday setups revolve around that range. A decisive move below $104,000 could trigger short-term unwind pressure toward $102,000-$103,000, where liquidity is more pronounced on Coinbase order books.

Holding above $106,000-$107,000, on the other hand, would signal resilience and may realign futures with spot without a deep retrace.

For context, the CME has recorded four material weekend gaps since late summer. Three closed within 24-48 hours; one, from early September, stayed open for more than a week before eventually filling. These episodes tend to compress volatility temporarily before resuming the prior trend.

As the US market open nears, traders are watching whether the shutdown resolution and broader risk-on tone provide enough momentum to keep Bitcoin from revisiting the full $104k-$110k range, or if the futures magnet pulls it back once again.

The post BTC targets CME gap at $104,000 as shutdown end buoys risk appeared first on CryptoSlate.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Citrini, once the most prominent bull in AI hardware, has now significantly reduced his semiconductor holdings and currently holds some short positions. He believes that the financing structure for AI infrastructure has shifted from tech giants' own cash flows to equity and debt markets, and that sentiment alone could sever the funding chain and impact fundamentals. Strategically, he is long Meta and short Google. Citrini also asserts that the bottleneck in AI pharmaceutical development is not computational power, but rather a "lack of monkeys."

华尔街见闻•2026/10/26 03:36
Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business

Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.

智通财经•2026/10/26 03:11

Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital

As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.

智通财经•2026/10/26 02:43